市場調查報告書

全球神經膠質母細胞瘤市場:至2025年的預測

Global Glioblastoma Market Research Report Forecast to 2025

出版商 Market Research Future 商品編碼 918819
出版日期 內容資訊 英文 133 Pages
訂單完成後即時交付
價格
全球神經膠質母細胞瘤市場:至2025年的預測 Global Glioblastoma Market Research Report Forecast to 2025
出版日期: 2019年11月30日內容資訊: 英文 133 Pages
簡介

全球神經膠質母細胞瘤市場至2025年預計將以以7.4%成長,2025年達到16億4,340萬美元的規模。開發替代傳統治療的低成本替代治療的獎勵有促進該市場的演進的可能性。

本報告提供全球神經膠質母細胞瘤市場的相關調查,市場機會,成長及阻礙因素,各類型、治療方法、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 摘要整理

  • 市場概要
  • 主要的貢獻要素
  • 市場魅力分析
  • 各類型
  • 各治療
  • 各終端用戶

第2章 市場簡介

  • 定義
  • 調查範圍
  • 調查目的
  • 市場結構
  • 前提條件、限制

第3章 調查方法

  • 資料探勘
  • 二次調查
  • 一次調查
  • 主要的受訪者的明細
  • 預測技術
  • 市場規模估計的調查方法
    • Bottom-Up(由下而上)方法
    • Top-Down(由上而下)方法
  • 資料的三角形分割
  • 檢驗

第4章 市場動態

  • 概要
  • 成長要素
    • 神經膠質母細胞瘤及腦瘤的發生率增加
    • 神經膠質母細胞瘤及腦瘤相關研究的增加
    • 化療的普及
    • 高齡人口的增加
    • 平均每人的醫療費的上升
    • 償付方案的增加
    • 神經膠質母細胞瘤的新的治療選擇
    • 產品核可的增加
    • 主要企業的合作的增加
    • 開發平台醫藥品數的增加
    • 法規機關的支援的增加
    • 政府機關的舉措增加
  • 阻礙因素
    • 臨床試驗的結束
    • 產品的高成本
    • 神經膠質母細胞瘤治療的臨床試驗設計的彈性低
    • 醫藥品成本的變動
  • 市場機會
    • 神經膠質母細胞瘤治療的今後的方法
    • 擴大到市場未開發的地區

第5章 市場要素分析

  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 新加入廠商的威脅
    • 替代威脅
    • 產業內的競爭
  • 價值鏈分析
    • 研究開發與設計
    • 製造業
    • 分佈
    • 行銷銷售
    • 銷售後的監測
  • 臨床實驗分析
    • 概要
    • 進行中的臨床實驗
    • 完成的臨床實驗
    • 終結的臨床實驗
    • 開發平台藥物的清單

第6章 市場分析:各類型

  • 概要
  • 原發性神經膠質母細胞瘤
  • 續發性神經膠質母細胞瘤

第7章 市場分析:各治療法

  • 概要
  • 手術
  • 放射線治療
  • 化療
  • 其他

第8章 市場分析:各終端用戶

  • 概要
  • 醫院
  • 專門診所、中心
  • 其他

第9章 市場分析:各地區

  • 概要
  • 南北美洲
    • 北美
    • 南美
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 亞太地區
  • 中東、非洲
    • 中東
    • 非洲

第10章 競爭情形

  • 概要
  • 企業佔有率分析
  • 主要的開發
    • 新產品的銷售/核准
    • 合併、收購
    • 產品開發

第11章 企業簡介

  • F. HOFFMANN-LA ROCHE LTD
  • ARBOR PHARMACEUTICALS, LLC
  • MERCK & CO., INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • SUN PHARMACEUTICAL INDUSTRIES LTD
  • AMGEN INC.

第12章 附錄

  • 參考文獻
  • 相關報告
目錄

Global Glioblastoma Market: Information by Type (Primary Glioblastoma and Secondary Glioblastoma), by Treatment (Surgical Procedure, Radiation Therapy, Chemotherapy and others), by End User (Hospitals, Specialty Clinics & Centers and others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Market analysis

Globally, the increasing frequency rate of glioblastoma is expected to fuel the growth in the glioblastoma market. According to the figures issued in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastoma has an occurrence rate of 3.19 per 100,000 people in the US. The Global Glioblastoma Market is projected to enroll a CAGR of 7.40% to reach 1,643.4 million by 2025. The rising popularity tacitly raises the healthcare outlay of the people as well as the administration. This encourages the performers operational in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the evolution of the global glioblastoma market through the forecast period. Glioblastoma is a type of brain tumor. According to the statistics available in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastoma has an occurrence rate of 3.19 per 100,000 persons in the US. The growing popularity indirectly increases the healthcare outlay of the people as well as the regime. In May 2019, Merck entered into a final accord to acquire Peloton Therapeutics, Inc., a confidentially held, clinical-stage biopharmaceutical company, focused on the development of novel small molecule therapeutic candidates aiming hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology disorders. Some of the key policies pursued by players operating in the global glioblastoma market were modernization, product expansion, and acquisition & mergers. Likewise, the fact that glioma stem cells survive traditional medicines also heightens vital necessary for unconventional care medications for glioblastoma multiforme thus pushing the market. Improving R&D in gene analysis and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market expansion over the forecast period. However, high expenditure involved in research employing genomics-based research is a crucial power for market. This motivates the players operating in the market to come up with replacements for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma market during the prediction period. The increasing incidents of glioblastoma, a type of brain tumor, combined with broad research in glioblastoma treatment, and the rising adoption of chemotherapy are expected to fuel the growth of the global glioblastoma market. However, the high cost of drugs and the failure of drug candidates in clinical trial phases are expected to impede the market growth.

Market segmentation

The Global Glioblastoma Market is segmented based on material type, treatment, end user and region respectively. The increasing prevalence rate of glioblastoma is projected to fuel the growth of the global glioblastoma market. Based on treatment, the glioblastoma market has been isolated into surgical technique, radioactivity therapy, chemotherapy, and others. The global glioblastoma market, based on end user, has been separated into hospitals, specialty clinics and centers, and others. The specialty clinics and centers held a share of 36.8% in 2018. In January 2018, Amgen and Allergan PLC received the approval by the European Commission (EC) for the marketing authorization of MVASI for the treatment of glioblastoma as well as certain types of cancers. The global glioblastoma market has been given by type, medication, and end user. The market, based on type, has been bifurcated into major glioblastoma and secondary glioblastoma. In November 2016, Sun Pharma acquired Biosintez, a Russian pharmaceutical company employed in the manufacturing and marketing of pharmaceutical products. There is a noteworthy absence of actual restorations in the present market owing to the incapability of medicines to pierce the blood brain fence, with the only stressed treatment putative actuality Roche's Avastin (bevacizumab) for recurring GBM patients in spite of the rehabilitation not representing a existence advantage in patients. It is also researched that ever since patients have no real therapy alternatives and low endurance probability there's a likelihood for high realization in the marketplace if a mediator is competent of boosting endurance or condition of a lifetime.

Regional analysis

Geographically the Global Glioblastoma Market is split in regions like North & South America, Europe, Asia-Pacific, Middle east and Africa and Rest of the world. Europe held a significant share in the global glioblastoma market. This can be credited to a large number of clinical trials in the region. For instance, Merck KGaA along with Vaximm GmbH is complex in Phase I and II trials to evaluate the efficacy and safety of VXM01 in combination with Avelumab in patients with resectable and non-resectable progressive glioblastoma following tumor resection and radio-chemotherapy containing temozolomide. The Americas is likely to dictate the global glioblastoma market. The growth in this region can be ascribed to the increased cases of glioblastoma and brain tumors. Moreover, the approval of drugs helps in boosting the expansion of the market in this region. The glioblastoma market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth in this region. Rising awareness regarding health and accessibility of new treatment methods are expected to drive the market growth during the evaluation period. Asia-Pacific is estimated to be the quickest-growing region in the global market. The rise in the enhanced healthcare infrastructure promises a high level of research on the therapy of glioblastoma in the region.

Major players

The proposed spectators in the Global Glioblastoma Market are manufacturers, Retailers, distributors, wholesalers, Investors and trade experts, Governments, associations, industrial bodies, etc. The major companies functioning in the Global Glioblastoma Market are concentrating on firming their global ways by entering into untouched markets. The projected onlookers in the Global Glioblastoma Market are companies like Teva Pharmaceutical Industries Ltd (Israel), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), etc.

Table of Contents

1 EXECUTIVE SUMMARY

  • 1.1 MARKET SYNOPSIS
  • 1.2 KEY CONTRIBUTING FACTORS
  • 1.3 MARKET ATTRACTIVENESS ANALYSIS
  • 1.4 GLOBAL GLIOBLASTOMA MARKET, BY TYPE
  • 1.5 GLOBAL GLIOBLASTOMA MARKET, BY TREATMENT
  • 1.6 GLOBAL GLIOBLASTOMA MARKET, BY END USER

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE
  • 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 INCREASING INCIDENCE RATE OF GLIOBLASTOMA AND BRAIN CANCER
    • 4.2.2 INCREASING RESEARCH ON GLIOBLASTOMA AND BRAIN TUMORS
    • 4.2.3 RISING ADOPTION OF CHEMOTHERAPY
    • 4.2.4 INCREASING GERIATRIC POPULATION
    • 4.2.5 RISING PER CAPITA HEALTHCARE EXPENDITURE
    • 4.2.6 INCREASING REIMBURSEMENT SCENARIO
    • 4.2.7 NEW TREATMENT OPTIONS FOR GLIOBLASTOMA
    • 4.2.8 RISE IN PRODUCT APPROVALS
    • 4.2.9 RISING COLLABORATIONS BY KEY PLAYERS
    • 4.2.10 INCREASING NUMBER OF PIPELINE DRUGS
    • 4.2.11 INCREASING SUPPORT BY REGULATORY BODIES
    • 4.2.12 INCREASED INITIATIVES BY GOVERNMENT ORGANIZATIONS
  • 4.3 RESTRAINTS
    • 4.3.1 TERMINATION OF CLINICAL TRIALS
    • 4.3.2 HIGH COST OF PRODUCTS
    • 4.3.3 LESS FLEXIBILITY IN CLINICAL TRIAL DESIGN FOR GLIOBLASTOMA TREATMENT
    • 4.3.4 VARIATION IN COST OF DRUGS
  • 4.4 OPPORTUNITIES
    • 4.4.1 UPCOMING APPROACHES FOR THE TREATMENT OF GLIOBLASTOMA
    • 4.4.2 EXPANSION IN UNTAPPED REGIONS

5 MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES MODEL
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 VALUE CHAIN ANALYSIS
    • 5.2.1 R&D AND DESIGNING
    • 5.2.2 MANUFACTURING
    • 5.2.3 DISTRIBUTION
    • 5.2.4 MARKETING & SALES
    • 5.2.5 POST-SALES MONITORING
  • 5.3 CLINICAL TRIAL ANALYSIS
    • 5.3.1 OVERVIEW
    • 5.3.2 ONGOING CLINICAL TRIALS
    • 5.3.3 COMPLETED CLINICAL TRIALS
    • 5.3.4 TERMINATED CLINICAL TRIALS
    • 5.3.5 LIST OF PIPELINE DRUGS

6 GLOBAL GLIOBLASTOMA MARKET BY TYPE

  • 6.1 OVERVIEW
  • 6.2 PRIMARY GLIOBLASTOMA
  • 6.3 SECONDARY GLIOBLASTOMA

7 GLOBAL GLIOBLASTOMA MARKET BY TREATMENT

  • 7.1 OVERVIEW
  • 7.2 SURGICAL PROCEDURE
  • 7.3 RADIATION THERAPY
  • 7.4 CHEMOTHERAPY
  • 7.5 OTHERS

8 GLOBAL GLIOBLASTOMA MARKET BY END USER

  • 8.1 OVERVIEW
  • 8.2 HOSPITALS
  • 8.3 SPECIALTY CLINICS & CENTERS
  • 8.4 OTHERS

9 GLOBAL GLIOBLASTOMA MARKET BY REGION

  • 9.1 OVERVIEW
  • 9.2 AMERICAS
    • 9.2.1 NORTH AMERICA
      • 9.2.1.1 US
      • 9.2.1.2 CANADA
    • 9.2.2 LATIN AMERICA
  • 9.3 EUROPE
    • 9.3.1 WESTERN EUROPE
      • 9.3.1.1 GERMANY
      • 9.3.1.2 FRANCE
      • 9.3.1.3 UK
      • 9.3.1.4 ITALY
      • 9.3.1.5 SPAIN
      • 9.3.1.6 REST OF WESTERN EUROPE
    • 9.3.2 EASTERN EUROPE
  • 9.4 ASIA-PACIFIC
    • 9.4.1 JAPAN
    • 9.4.2 CHINA
    • 9.4.3 AUSTRALIA
    • 9.4.4 INDIA
    • 9.4.5 SOUTH KOREA
    • 9.4.6 REST OF ASIA-PACIFIC
  • 9.5 MIDDLE EAST & AFRICA
    • 9.5.1 MIDDLE EAST
    • 9.5.2 AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 COMPANY SHARE ANALYSIS
  • 10.3 KEY DEVELOPMENTS
    • 10.3.1 NEW PRODUCT LAUNCH/APPROVAL
    • 10.3.2 MERGERS & ACQUISITIONS
    • 10.3.3 PRODUCT DEVELOPMENT

11 COMPANY PROFILE

  • 11.1 F. HOFFMANN-LA ROCHE LTD
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS/SERVICES OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 ARBOR PHARMACEUTICALS, LLC
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS/SERVICES OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 KEY STRATEGIES
  • 11.3 MERCK & CO., INC.
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS/SERVICES OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 SWOT ANALYSIS
    • 11.3.6 KEY STRATEGIES
  • 11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS/SERVICES OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
    • 11.4.6 KEY STRATEGIES
  • 11.5 SUN PHARMACEUTICAL INDUSTRIES LTD
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS/SERVICES OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 SWOT ANALYSIS
    • 11.5.6 KEY STRATEGIES
  • 11.6 AMGEN INC.
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS/SERVICES OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 SWOT ANALYSIS
    • 11.6.6 KEY STRATEGIES

12 APPENDIX

  • 12.1 REFERENCES
  • 12.2 RELATED REPORTS

List of Tables

  • TABLE 1 LIST OF ASSUMPTIONS
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • TABLE 3 GLIOBLASTOMA: ONGOING CLINICAL TRIALS
  • TABLE 4 GLIOBLASTOMA: COMPLETED CLINICAL TRIALS
  • TABLE 5 TERMINATED CLINICAL TRIALS FOR GLIOBLASTOMA
  • TABLE 6 GLIOBLASTOMA: PIPELINE DRUGS
  • TABLE 7 GLOBAL GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 8 GLOBAL GLIOBLASTOMA MARKET FOR PRIMARY GLIOBLASTOMA, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 9 GLOBAL GLIOBLASTOMA MARKET FOR SECONDARY GLIOBLASTOMA, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 10 GLOBAL GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 11 GLOBAL GLIOBLASTOMA MARKET FOR SURGICAL PROCEDURE, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 12 GLOBAL GLIOBLASTOMA MARKET FOR RADIATION THERAPY, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 13 GLOBAL GLIOBLASTOMA MARKET FOR CHEMOTHERAPY, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 14 GLOBAL GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 15 GLOBAL GLIOBLASTOMA MARKET FOR HOSPITALS, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 16 GLOBAL GLIOBLASTOMA MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 17 GLOBAL GLIOBLASTOMA MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 18 AMERICAS: GLIOBLASTOMA MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 19 AMERICAS: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 20 AMERICAS: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 21 AMERICAS: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 22 NORTH AMERICA: GLIOBLASTOMA MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 23 NORTH AMERICA: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 24 NORTH AMERICA: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 25 NORTH AMERICA: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 26 US: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 27 US: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 28 US: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 29 CANADA: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 30 CANADA: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 31 CANADA: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 32 LATIN AMERICA: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 33 LATIN AMERICA: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 34 LATIN AMERICA: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 35 EUROPE: GLIOBLASTOMA MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 36 EUROPE: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 37 EUROPE: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 38 EUROPE: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 39 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 40 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 41 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 42 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 43 GERMANY: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 44 GERMANY: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 45 GERMANY: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 46 FRANCE: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 47 FRANCE: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 48 FRANCE: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 49 UK: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 50 UK: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 51 UK: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 52 ITALY: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 53 ITALY: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 54 ITALY: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 55 SPAIN: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 56 SPAIN: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 57 SPAIN: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 58 REST OF WESTERN EUROPE: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 59 REST OF WESTERN EUROPE: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 60 REST OF WESTERN EUROPE: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 61 EASTERN EUROPE: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 62 EASTERN EUROPE: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 63 EASTERN EUROPE: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 64 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 65 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 66 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 67 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 68 JAPAN: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 69 JAPAN: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 70 JAPAN: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 71 CHINA: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 72 CHINA: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 73 CHINA: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 74 AUSTRALIA: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 75 AUSTRALIA: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 76 AUSTRALIA: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 77 INDIA: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 78 INDIA: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 79 INDIA: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 80 SOUTH KOREA: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 81 SOUTH KOREA: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 82 SOUTH KOREA: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 83 REST OF ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 84 REST OF ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 85 REST OF ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 86 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 87 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 88 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 89 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 90 MIDDLE EAST: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 91 MIDDLE EAST: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 92 MIDDLE EAST: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 93 AFRICA: GLIOBLASTOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 94 AFRICA: GLIOBLASTOMA MARKET, BY TREATMENT, 2016-2025 (USD MILLION)
  • TABLE 95 AFRICA: GLIOBLASTOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 96 NEW PRODUCT LAUNCH/APPROVAL
  • TABLE 97 MERGERS & ACQUISITIONS
  • TABLE 98 PRODUCT DEVELOPMENT
  • TABLE 99 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 100 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS
  • TABLE 101 ARBOR PHARMACEUTICALS, LLC: PRODUCTS/SERVICES OFFERED
  • TABLE 102 ARBOR PHARMACEUTICALS, LLC: KEY DEVELOPMENTS
  • TABLE 103 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 104 MERCK & CO., INC.: KEY DEVELOPMENTS
  • TABLE 105 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 106 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 107 SUN PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
  • TABLE 108 AMGEN INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 109 AMGEN INC.: KEY DEVELOPMENTS

List of Figures

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS (2018)
  • FIGURE 3 GLOBAL GLIOBLASTOMA MARKET ANALYSIS, BY TYPE
  • FIGURE 4 GLOBAL GLIOBLASTOMA MARKET ANALYSIS, BY TREATMENT
  • FIGURE 5 GLOBAL GLIOBLASTOMA MARKET ANALYSIS, BY END USER
  • FIGURE 6 GLOBAL GLIOBLASTOMA MARKET: STRUCTURE
  • FIGURE 7 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 8 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL GLIOBLASTOMA MARKET
  • FIGURE 9 DRIVERS: IMPACT ANALYSIS
  • FIGURE 10 RESTRAINTS: IMPACT ANALYSIS
  • FIGURE 11 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GLIOBLASTOMA MARKET
  • FIGURE 12 VALUE CHAIN ANALYSIS OF THE GLOBAL GLIOBLASTOMA MARKET
  • FIGURE 13 GLOBAL GLIOBLASTOMA MARKET SHARE, BY TYPE, 2018 (%)
  • FIGURE 14 GLOBAL GLIOBLASTOMA MARKET, BY TYPE, 2018 AND 2025 (USD MILLION)
  • FIGURE 15 GLOBAL GLIOBLASTOMA MARKET SHARE, BY TREATMENT, 2018 (%)
  • FIGURE 16 GLOBAL GLIOBLASTOMA MARKET, BY TREATMENT, 2018 AND 2025 (USD MILLION)
  • FIGURE 17 GLOBAL GLIOBLASTOMA MARKET SHARE, BY END USER, 2018 (%)
  • FIGURE 18 GLOBAL GLIOBLASTOMA MARKET, BY END USER, 2018 AND 2025 (USD MILLION)
  • FIGURE 19 GLOBAL GLIOBLASTOMA MARKET SHARE, BY REGION, 2018 (%)
  • FIGURE 20 GLOBAL GLIOBLASTOMA MARKET, BY REGION, 2018 AND 2025 (USD MILLION)
  • FIGURE 21 AMERICAS: GLIOBLASTOMA MARKET, BY REGION, 2018 AND 2025
  • FIGURE 22 NORTH AMERICA: GLIOBLASTOMA MARKET, BY COUNTRY, 2018 AND 2025
  • FIGURE 23 EUROPE: GLIOBLASTOMA MARKET, BY REGION, 2018 AND 2025
  • FIGURE 24 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY COUNTRY, 2018 AND 2025
  • FIGURE 25 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY COUNTRY, 2018 AND 2025
  • FIGURE 26 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY REGION, 2018 AND 2025
  • FIGURE 27 MAJOR PLAYER MARKET SHARE ANALYSIS, 2018 (%)
  • FIGURE 28 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 29 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
  • FIGURE 30 ARBOR PHARMACEUTICALS, LLC: SWOT ANALYSIS
  • FIGURE 31 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 32 MERCK & CO., INC.: SWOT ANALYSIS
  • FIGURE 33 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
  • FIGURE 35 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 36 SUN PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
  • FIGURE 37 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 38 AMGEN INC.: SWOT ANALYSIS